Nikhil C. Munshi, MD

Articles

Dr. Munshi on the FDA Approval of Idecabtagene Vicleucel in Multiple Myeloma

March 29th 2021

Nikhil C. Munshi, MD, discusses the FDA approval of idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Dr. Munshi on Next Steps With Idecabtagene Vicleucel in R/R Multiple Myeloma

July 6th 2020

Nikhil C. Munshi, MD, discusses the next steps for research with idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Dr. Munshi on T-Cell Persistence With Ide-Cel in R/R Multiple Myeloma

July 6th 2020

Nikhil C. Munshi, MD, discusses T-cell persistence with ​idecabtagene vicleucel demonstrated in the phase 2 KarMMA trial in patients with relapsed /refractory multiple myeloma.

Dr. Munshi on the Current Landscape of CAR T-Cell Therapy in Multiple Myeloma

June 30th 2020

Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Munshi on the Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

May 29th 2020

Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Munshi on Testing for MRD in Multiple Myeloma

March 21st 2020

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Kraft Family Chair, senior physician, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses ways to test for minimal residual disease (MRD) in multiple myeloma.

Dr. Munshi on the Antitumor Effect of NKTR-255 in Patients With Myeloma

January 17th 2020

Nikhil C. Munshi, MD, discusses the antitumor effect of NKTR-255 in patients with multiple myeloma.

Dr. Munshi on the Role of Checkpoint Inhibitors in Myeloma

August 29th 2018

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the role of checkpoint inhibitors in myeloma.

Dr. Munshi on Latest Treatment Developments in Multiple Myeloma

August 16th 2018

Nikhil C. Munshi, MD, director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the latest treatment developments for patients with multiple myeloma.